study to evaluate different extended release (ER)-formulations and multiple ascending dosing of AZD3241
Study identifier:D0490C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 after Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers including food effect
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD3241, Placebo Tablet
Sex
All
Actual Enrollment
77
Study type
Interventional
Age
30 Years - 65 Years
Date
Study Start Date: 01 Jun 2009
Primary Completion Date: 01 Mar 2010
Study Completion Date: 01 Mar 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Apr 2010 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD3241 AZD3241 Tablets | Drug: AZD3241 Oral Tablet, Repeated Administration |
| Experimental: Placebo Placebo Tablets | Drug: Placebo Tablet Oral Tablet. Repeated Administration |
Contacts
Investigators
Principal Investigator
Rolf Karlsten
Medical Science Director AstraZeneca R&D Södertälje.
